Truveta Inc.

Truveta Inc. is a US-based technology firm specializing in healthcare data analytics, providing organizations with actionable insights derived from extensive electronic health records to improve patient outcomes. Founded in 2020 and headquartered in Washington, US, Truveta Inc. focuses on leveraging electronic health record data for healthcare analytics.

The company was established by CEO Terry Myerson, CTO Jay Nanduri and CMO Ryan Ahern. Truveta has completed 3 funding deals, with the most recent being a Series C round on January 13, 2025, raising USD 200. 00 mn from investors including Illumina, Inc. and Regeneron Pharmaceuticals, Inc.

The total amount raised by the firm stands at USD 200. 00 mn, with a current valuation of USD 1. 65 bn. Truveta's primary offerings center around its extensive electronic health record (EHR) data and analytics platform, aggregating data from over 120 million patients, including clinical notes, images, and linked closed claims from 200 million patients.

This platform enables healthcare organizations to derive actionable insights on medical devices and disease states, addressing disparities in healthcare access. Truveta's solutions support life sciences, healthcare research, and public health sectors, enhancing drug discovery, optimizing clinical trials, and improving disease prevention and diagnosis. The company serves a diverse client base, including major health systems, pharmaceutical companies, and public health organizations, primarily in the US, with goals for global expansion. Truveta operates on a subscription-based revenue model, granting clients access to regulatory-grade EHR data and analytics tools.

Clients, including healthcare organizations and life science entities, utilize Truveta's comprehensive data for safety evaluations, health economics and outcomes research (HEOR), and clinical trial support. Collaborations with healthcare providers facilitate continuous data exchange, enhancing insights and analytics. Pricing structures for services are tailored to the needs of individual clients. Key products such as the Truveta Language Model and Truveta Studio are integral to supporting stakeholders in improving patient care and healthcare delivery.

In January 2025, Truveta Inc. secured USD 200. 00 mn in Series C funding to support the launch of its Truveta Genome Project. The company aims to expand its offerings and enhance its platform capabilities.

Future initiatives include targeting new geographic markets to broaden its client base and further develop its data analytics services. The recent funding will enable Truveta to invest in product development and market expansion efforts.